Skip to main content
SpringerLink
Log in

High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis

  • Original Article
  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

Transcriptional coactivator p300 has been shown to play a variety of roles in the transcription process and mutation of p300 has been found in certain types of human cancers. However, the expression dynamics of p300 in breast cancer (BC) and its effect on BC patients’ prognosis are poorly understood.

Methods

In the present study, the methods of tissue microarray and immunohistochemistry (IHC) were used to investigate the protein expression of p300 in BCs. Receiver operating characteristic (ROC) curve analysis, Spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were utilized to analyze the data.

Results

Based on the ROC curve analysis, the cutoff value for p300 high expression was defined when the H score for p300 was more than 105. High expression of p300 could be observed in 105/193 (54.4%) of BCs, in 6/25 (24.0%) of non-malignant breast tissues, respectively (P=0.004). Further correlation analysis showed that high expression of p300 was positively correlated with higher histological grade, advanced clinical stage and tumor recurrence (P<0.05). In univariate survival analysis, a significant association between high expression of p300 and shortened patients’ survival and poor progression-free survival was found (P<0.05). Importantly, p300 expression was evaluated as an independent prognostic factor in multivariate analysis (P<0.05).

Conclusion

Our findings provide a basis for the concept that high expression of p300 in BC may be important in the acquisition of a recurrence phenotype, suggesting that p300 high expression, as examined by IHC, is an independent biomarker for poor prognosis of patients with BC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108.

    Article  PubMed  Google Scholar 

  2. Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 2010; 29:16.

    Article  PubMed  Google Scholar 

  3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784–1792.

    Article  PubMed  CAS  Google Scholar 

  4. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133–1144.

    Article  PubMed  CAS  Google Scholar 

  5. Coleman MP, Quaresma M, Berrino F, et al: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9:730–756.

    Article  PubMed  Google Scholar 

  6. Kundu TK, Palhan VB, Wang Z, et al. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell 2000; 6:551–561.

    Article  PubMed  CAS  Google Scholar 

  7. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001; 276:13505–13508.

    PubMed  CAS  Google Scholar 

  8. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000; 14:1553–1577.

    PubMed  CAS  Google Scholar 

  9. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12:1565–1569.

    PubMed  CAS  Google Scholar 

  10. Gayther SA, Batley SJ, Linger L, et al: Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300–303.

    Article  PubMed  CAS  Google Scholar 

  11. Fan S, Ma YX, Wang C, et al: p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002; 62:141–151.

    PubMed  CAS  Google Scholar 

  12. Bandyopadhyay D, Okan NA, Bales E, et al. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002; 62:6231–6239.

    PubMed  CAS  Google Scholar 

  13. Li M, Luo RZ, Chen JW, et al. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 2011; 9:5.

    Article  PubMed  Google Scholar 

  14. Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol 2009; 29:1749–1759.

    Article  PubMed  CAS  Google Scholar 

  15. Fermento ME, Gandini NA, Lang CA, et al. Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer. Exp Mol Pathol 2010; 88:256–264.

    Article  PubMed  CAS  Google Scholar 

  16. Vleugel MM, Shvarts D, van der Wall E, et al. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol 2006; 37:1085–1092.

    Article  PubMed  CAS  Google Scholar 

  17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–410.

    Article  PubMed  CAS  Google Scholar 

  18. Wittekind C. 2010 TNM system: on the 7th edition of TNM classification of malignant tumors. Pathologe 2010; 31:331–332.

    Article  PubMed  CAS  Google Scholar 

  19. Cai MY, Zhang B, He WP, et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010; 101:1543–1549.

    Article  PubMed  CAS  Google Scholar 

  20. Abubaker J, Bavi P, Al-Haqawi W, et al. PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 2009; 8:51.

    Article  PubMed  Google Scholar 

  21. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60:1112–1116.

    Article  PubMed  Google Scholar 

  22. Ishihama K, Yamakawa M, Semba S, et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 2007; 60:1205–1210.

    Article  PubMed  CAS  Google Scholar 

  23. Debes JD, Sebo TJ, Lohse CM, et al. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63:7638–7640.

    PubMed  CAS  Google Scholar 

  24. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res 2007; 17:324–332.

    Article  PubMed  CAS  Google Scholar 

  25. Borrow J, Stanton VP, Jr., Andresen JM, et al: The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14:33–41.

    Article  PubMed  CAS  Google Scholar 

  26. Kurebayashi J, Otsuki T, Kunisue H, et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000; 6:512–518.

    PubMed  CAS  Google Scholar 

  27. De-Carvalho MC, Chimelli LM, Quirico-Santos T. Modulation of fibronectin expression in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis. Braz J Med Biol Res 1999; 32:583–592.

    Article  PubMed  CAS  Google Scholar 

  28. Hudelist G, Czerwenka K, Kubista E, et al. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003; 78:193–204.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, Guangzhou, 510060, China

    Xiang-sheng Xiao, Mu-yan Cai, Jie-wei Chen, Xin-yuan Guan, Hsiang-fu Kung, Yi-xin Zeng & Dan Xie

  2. Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

    Xiang-sheng Xiao

  3. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

    Mu-yan Cai & Jie-wei Chen

  4. The Chinese University of Hong Kong, Hong Kong, China

    Hsiang-fu Kung

Authors
  1. Xiang-sheng Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mu-yan Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie-wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin-yuan Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hsiang-fu Kung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-xin Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan Xie.

Additional information

This work was supported by a grant from the National Natural Science Foundation of China (No.30901709), the National “973” Basic Research Program of China (No. 2010CB529400 and 2010CB912802).

Contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiao, Xs., Cai, My., Chen, Jw. et al. High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis. Chin. J. Cancer Res. 23, 201–207 (2011). https://doi.org/10.1007/s11670-011-0201-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-011-0201-5

Key words

Search

Navigation